Display options
Cite
Imanishi S, Umezu T, Kobayashi C, et al. Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Front Pharmacol. 2018;9:1166doi: 10.3389/fphar.2018.01166.
Imanishi, S., Umezu, T., Kobayashi, C., Ohta, T., Ohyashiki, K., & Ohyashiki, J. H. (2018). Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Frontiers in pharmacology, 91166. https://doi.org/10.3389/fphar.2018.01166
Imanishi, Satoshi, et al. "Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells." Frontiers in pharmacology vol. 9 (2018): 1166. doi: https://doi.org/10.3389/fphar.2018.01166
Imanishi S, Umezu T, Kobayashi C, Ohta T, Ohyashiki K, Ohyashiki JH. Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells. Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018. PMID: 30386240; PMCID: PMC6198088.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2018 Oct 16;9:1166. doi: 10.3389/fphar.2018.01166. eCollection 2018.

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells.

Frontiers in pharmacology

Satoshi Imanishi, Tomohiro Umezu, Chiaki Kobayashi, Tomohiko Ohta, Kazuma Ohyashiki, Junko H Ohyashiki

Affiliations

  1. Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
  2. Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
  3. Department of Hematology, Tokyo Medical University, Tokyo, Japan.

PMID: 30386240 PMCID: PMC6198088 DOI: 10.3389/fphar.2018.01166

Abstract

Recent investigations of the treatment for hematologic neoplasms have focused on targeting epigenetic regulators. The DNA methyltransferase inhibitor 5-azacytidine (AZA) has produced good results in the treatment of patients with myelodysplastic syndromes. The mechanism underlying its pharmacological activity involves many cellular processes including histone modifications, but chromatin regulation in AZA-resistant cells is still largely unknown. Therefore, we compared human leukemia cells with AZA resistance and their AZA-sensitive counterparts with regard to the response of histone modifications and their readers to AZA treatment to identify novel molecular target(s) in hematologic neoplasms with AZA resistance. We observed an a decrease of HP1γ, a methylated lysine 9 of histone H3-specific reader protein, in AZA-sensitive cells after treatment, whereas AZA treatment did not affect HP1 family proteins in AZA-resistant cells. The expression of shRNA targeting HP1γ reduced viability and induced apoptosis specifically in AZA-resistant cells, which accompanied with down-regulation of ATM/BRCA1 signaling, indicating that chromatin regulation by HP1γ plays a key role in the survival of AZA-resistant cells. In addition, the amount of HP1γ protein in AZA-sensitive and AZA-resistant cells was decreased after treatment with the bromodomain inhibitor I-BET151 at a dose that inhibited the growth of AZA-resistant cells more strongly than that of AZA-sensitive cells. Our findings demonstrate that treatment with AZA, which affects an epigenetic reader protein and targets HP1γ, or a bromodomain inhibitor is a novel strategy that can be used to treat patients with hematopoietic neoplasms with AZA resistance.

Keywords: azacytidine; bromodomain inhibitor; drug resistance; heterochromatin protein 1; histone modification; leukemia

References

  1. Epigenetics. 2011 Feb;6(2):128-33 - PubMed
  2. Nat Genet. 2000 Jan;24(1):88-91 - PubMed
  3. Nat Cell Biol. 2006 Apr;8(4):407-15 - PubMed
  4. Nature. 2006 Feb 16;439(7078):871-4 - PubMed
  5. Epigenetics. 2014 Nov;9(11):1485-95 - PubMed
  6. Int J Hematol. 2016 Nov;104(5):566-573 - PubMed
  7. Biochem Pharmacol. 2014 Jun 1;89(3):361-9 - PubMed
  8. Cancer Res. 2015 Apr 1;75(7):1311-21 - PubMed
  9. Leukemia. 2014 Mar;28(3):621-8 - PubMed
  10. Epigenetics. 2010 May 16;5(4):287-92 - PubMed
  11. Bioessays. 2011 Apr;33(4):280-9 - PubMed
  12. Oncogene. 2013 May 30;32(22):2747-55 - PubMed
  13. Nucleic Acids Res. 2003 May 1;31(9):2305-12 - PubMed
  14. Curr Opin Chem Biol. 2017 Aug;39:116-125 - PubMed
  15. N Engl J Med. 2012 Aug 16;367(7):647-57 - PubMed
  16. Br J Cancer. 2005 May 23;92(10):1942-7 - PubMed
  17. Expert Opin Drug Discov. 2017 May;12(5):449-463 - PubMed
  18. Blood. 2012 May 31;119(22):5229-38 - PubMed
  19. Sci Rep. 2015 Nov 18;5:16709 - PubMed
  20. Leuk Res. 2016 Mar;42:68-74 - PubMed
  21. Leukemia. 2014 Feb;28(2):411-3 - PubMed
  22. Genome Biol. 2014 Aug 30;15(8):406 - PubMed
  23. Hematology Am Soc Hematol Educ Program. 2013;2013:511-21 - PubMed
  24. Int J Cancer. 2008 Jul 1;123(1):8-13 - PubMed
  25. Epigenetics. 2010 Apr;5(3):229-40 - PubMed
  26. Oncotarget. 2017 Apr 25;8(17):28812-28825 - PubMed
  27. Mol Cell. 2008 Jul 25;31(2):167-77 - PubMed
  28. Nat Genet. 2014 Apr;46(4):364-70 - PubMed
  29. Mol Cell. 2005 Aug 5;19(3):381-91 - PubMed

Publication Types